Other immune effector cells

The term Other immune effector cells refers to a broad and heterogeneous group of immune cells that exclude the primary adaptive lymphocytes, specifically T and B cells. This category typically includes innate immune cells such as natural killer (NK) cells, macrophages, neutrophils, dendritic cells, and eosinophils, which are responsible for the immediate response to pathogens and the orchestration of subsequent adaptive immunity (Source: NIH, National Cancer Institute). These cells execute their functions through various mechanisms, including direct cytotoxicity, phagocytosis, and the release of pro-inflammatory cytokines (Source: PubMed, PMID: 32665631). In the pharmaceutical industry, this designation is frequently used in clinical trial databases to categorize therapies that modulate these non-T-cell populations, such as NK cell-based immunotherapies or macrophage-polarizing agents (Source: Nature Reviews Drug Discovery, doi:10.1038/nrd.2017.243). Because it represents a collection of diverse cell types rather than a single molecular entity like a receptor or enzyme, it is not considered a specific therapeutic target in the traditional sense. Instead, it serves as a functional classification for cells that act as effectors in the immune system's defense against disease. Drugs associated with this category usually target specific surface receptors or signaling pathways unique to one of these cell types, such as CD16 on NK cells or CSF1R on macrophages. Consequently, this term is often considered a placeholder or a high-level grouping in drug discovery metadata rather than a precise molecular target.

Other names

Innate immune effector cellsNon-T non-B effector cellsMyeloid effector cellsNon-lymphocytic effector cellsInnate effector cells

Not applicable as this is a heterogeneous cell population category rather than a specific molecular target.